Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA

Replimune Reports Fiscal First Quarter 2025

Financial Results and Provides Corporate Update

Woburn, MA, August 8,

2024 - Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel

class of oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2024 and provided

"We have had a highly productive quarter as we gear up for the

upcoming pre-BLA meeting with the FDA and prepare to enroll the first patient in our confirmatory trial of RP1 in anti-PD1 failed melanoma,"

said Sushil Patel, Ph.D., CEO of Replimune. "Our confidence in the RP1 program is reinforced by the IGNYTE primary analysis data

that we presented in June, which demonstrates the potential of RP1 to address unmet needs in anti-PD1 failed melanoma patients who have

not responded to prior existing therapies. We remain committed to advancing the clinical programs in our pipeline, including RP2, where

we are preparing to enroll patients in a registration-directed study in uveal melanoma."

Program Highlights & Milestones

Financial Highlights

Based on the current

operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of June 30, 2024 will enable

the Company to fund operations into the second half of 2026 which includes scale up for the commercialization of RP1 in skin cancers and

for working capital and general corporate purposes.

RP1 (vusolimogene oderparepvec) is Replimune's lead product candidate

and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and

GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor

RP2 is based on a proprietary strain of herpes simplex virus engineered

and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity

of tumor cell death and the activation of a systemic anti-tumor immune response. RP2 additionally expresses an anti-CTLA-4 antibody-like

molecule, as well as GALV-GP R- and GM-CSF. RP2 is intended to provide targeted and potent delivery of these proteins to the sites of

immune response initiation in the tumor and draining lymph nodes, with the goal of focusing systemic-immune-based efficacy on tumors and

limiting off-target toxicity.

Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development

of a novel portfolio of oncolytic immunotherapies. Replimune's proprietary RPx platform is based on a potent HSV-1 backbone intended

to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a

unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of

tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates

are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed

alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Forward Looking Statements

This press release contains forward looking statements within the meaning

of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended,

including statements regarding our expectations about our cash runway, the design and advancement of our clinical trials, the timing and

sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize

our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified

by words such as "could," "expects," "intends," "may," "plans," "potential,"

"should," "will," "would," or similar expressions and the negatives of those terms. Forward-looking

statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which

are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements.

These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our

product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals,

the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject,

competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact

of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military

conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q

and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described

in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required

by law, we undertake no obligation to update or revise these forward-looking statements.

Replimune Group, Inc.

Condensed Consolidated Statements of Operations

(Amounts in thousands, except share and per

Replimune Group, Inc.

Condensed Consolidated Balance Sheets

(Amounts In thousands, except share and per